Operator
Good morning, and welcome to the Humacyte Virtual Webinar. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Humacyte website following the conclusion of the event.
I’d like to turn the call over to Dr. Laura E. Niklason, Founder, President and Chief Executive Officer of Humacyte. Please go ahead, Laura.
Laura Niklason
Founder, President, CEO & Director
Thank you, Tara, and welcome, everyone, to Humacyte’s virtual webinar describing the current unmet needs in dialysis access for patients who have kidney failure. As many of you know, we have been engaged in a Phase III program looking at the safety and the efficacy of Humacyte’s Acellular Tissue Engineered Vessel or ATEV, in its function as an access for hemodialysis and specifically comparing this access to patients who receive the current gold standard, which is fistula. Next slide, please.
These are just our disclaimers. Next slide. As you’ll see from this program, you’re going to hear from 2 important key opinion leaders discussing about the current unmet medical need and the current shortcomings of hemodialysis access and how Humacyte’s ATEV may be able to benefit some patients.
The first speaker will be Dr. Prabir Roy-Chaudhury, who is the Co-Director of the UNC Kidney Center and who is
